1.The incidences of autoantibodies after in vivo administration of interferon-gamma.
Myung Shik LEE ; Seong Hoe PARK ; Yong Seong KIM ; Noe Kyeong KIM ; Think You KIM
Journal of Korean Society of Endocrinology 1991;6(3):227-231
No abstract available.
Autoantibodies*
;
Incidence*
;
Interferon-gamma*
2.Decreased Serum Level of Interferon-gamma in Patients with Pityriasis Rosea.
Ming ZENG ; Shi Xiang ZHAO ; Ling Hua LIU ; Xian Bo ZUO ; Xiao Dong ZHENG ; Tao LI ; Min ZHANG ; Pei Guang WANG ; Sen YANG
Annals of Dermatology 2014;26(4):522-523
No abstract available.
Humans
;
Interferon-gamma*
;
Pityriasis Rosea*
3.Direct Cytotoxicity of Interferon-gamma (IFN-gamma) on Renal Cell Carcinoma Cell Line.
Jae Sik YOON ; Soo Jung YOON ; Min Ho SUH ; Seong Il SUH ; Won Ki BAEK ; Young Sun LEE ; Jong Wook PARK ; Sung Joo LEE
Korean Journal of Urology 2000;41(5):587-593
No abstract available.
Carcinoma, Renal Cell*
;
Cell Line*
;
Interferon-gamma*
4.Interferon-Gamma Release Assay in a Patient with Tuberculosis Verrucosa Cutis.
Geon KIM ; Young In JEONG ; Joon Won HUH ; Eun Jung KIM ; Ok Ja JOH
Annals of Dermatology 2015;27(1):109-110
No abstract available.
Humans
;
Interferon-gamma Release Tests*
;
Tuberculosis*
5.Phase II study of 5-fluorouracil and recombinant interferon-gamma in patients with advanced colorectal cancer.
Heung Tae KIM ; Chang In SUH ; Si Young KIM ; Dae Seog HEO ; Yung Jue BANG ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1992;24(5):743-758
No abstract available.
Colorectal Neoplasms*
;
Fluorouracil*
;
Humans
;
Interferon-gamma*
6.A Case of Lupus Vulgaris Diagnosed with Interferon-gamma Release Assay.
Do Hun KIM ; Nam Hee SUNG ; Sang Yun JIN ; Hyoseung SHIN ; Ai Young LEE ; Seung Ho LEE
Korean Journal of Dermatology 2014;52(4):279-281
No abstract available.
Interferon-gamma Release Tests*
;
Lupus Vulgaris*
7.Immunologic effects of recombinant gamma-interferon on human gastrointestinal tumor cell lines.
Doo Hyun CHUNG ; Young Mi BAE ; Jae Gahb PARK ; Sung Hoe PARK ; Yong Il KIM ; Sang Kook LEE
Journal of the Korean Cancer Association 1991;23(1):10-19
No abstract available.
Cell Line, Tumor*
;
Humans*
;
Interferon-gamma*
8.Factors Associated with a Strong Response to the T-SPOT.TB in Patients with Extrapulmonary Tuberculosis.
Yu Mi LEE ; Sun Mi KIM ; Su Jin PARK ; Sang Oh LEE ; Sang Ho CHOI ; Yang Soo KIM ; Jun Hee WOO ; Sung Han KIM
Infection and Chemotherapy 2014;46(4):248-252
Limited data are available on which factors are associated with strong immunologic responses to T-SPOT.TB. We investigated the factors associated with strong positive responses in patients with extrapulmonary tuberculosis (E-TB). Of 173 patients with E-TB who gave positive results on T-SPOT.TB, 26 (15%) with a strong positive response (defined as > or =1,000 spot-forming units (SFU)/2.5x10(5) PBMC to ESAT-6 or CFP-10) and 71 (41%) with a low positive response (< or = 99 SFU (6-99 SFU)/2.5x10(5) PBMC) were further analyzed. Miliary TB was independently associated with a strong positive response to T-SPOT.TB, while advanced age and immunosuppression were independently associated with weak positive T-SPOT.TB responses.
Humans
;
Immunosuppression
;
Interferon-gamma Release Tests
;
Tuberculosis*
9.Emerging pathogenic role of group 3 innate lymphoid cells in inflammatory diseases.
Hui-Xin XIE ; Yun GUO ; Hao-Jie ZHONG ; Yi ZHOU ; Xue-Qing YU
Acta Physiologica Sinica 2022;74(2):265-275
Group 3 innate lymphoid cells (ILC3) as a family member of innate lymphoid cells (ILCs), have been defined as novel innate immune cells in the past decade. ILC3 include a variety of heterogenous subsets with different phenotypes and functions, which are mainly distributed in barrier organs such as the intestine, lung and skin. They play an important role in immune regulation, tissue repair and lymphoid tissue formation. However, in various inflammatory diseases, ILC3 become dysregulated and participate in the pathogenesis through secreting a series of cytokines such as interleukin (IL)-17, IL-22, interferon-γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to modulate other immune cells and induce the formation of ectopic lymphoid structures. Therefore, it is of great significance to explore the phenotype and function of ILC3 in order to advance the understanding of inflammatory diseases and find new therapeutic targets. In this article, the phenotypic characteristics, biological functions and research progress of ILC3 in inflammatory diseases were reviewed.
Cytokines
;
Immunity, Innate
;
Interferon-gamma
;
Intestines
;
Lymphocytes
Result Analysis
Print
Save
E-mail